REPUBLIC HC to Invest in Langu Valley Biotechnology for Biotech Expansion

REPUBLIC HC, a prominent healthcare company, has announced its intention to invest in Langu Valley Biotechnology through a capital increase and share expansion method. The company's board of directors declared on April 11, 2025, that an investment agreement had been signed with Langu Valley Biotechnology. The agreement stipulates that REPUBLIC HC or its subsidiaries will invest in Langu Valley Biotechnology by increasing capital and expanding shares. The actual investment amount and other details are yet to be disclosed.

This strategic move by REPUBLIC HC is aimed at strengthening its position in the biotechnology sector. By investing in Langu Valley Biotechnology, REPUBLIC HC seeks to leverage the latter's expertise and resources to enhance its own capabilities in biotechnology research and development. This investment is expected to foster innovation and drive growth in the biotechnology industry, benefiting both companies in the long run.

The decision to invest in Langu Valley Biotechnology was made after extensive discussions and evaluations. REPUBLIC HC recognized the significant investment value of Langu Valley Biotechnology, which is controlled by Ding Xing, the ultimate beneficial owner of another company, Chengdu Langu Valley Biotechnology. The investment is seen as a strategic move to capitalize on Langu Valley Biotechnology's advanced technology in personalized DC vaccine treatment for malignant tumors, which has been approved for clinical use by the Hainan Boao Lek City International Medical Tourism Pilot Zone Medical and Drug Supervision Management Bureau in February 2025.

This approval marks a transition for Langu Valley Biotechnology from a continuous research and development company to a profitable entity capable of generating revenue through the use of its technology in designated hospitals. The investment is expected to have a significant strategic impact on REPUBLIC HC, helping the company leverage advanced technology to expand into the Southeast Asian market and the broader Chinese market. This move is also anticipated to enhance REPUBLIC HC's investment returns and create new market opportunities and commercial value for both parties.

The investment agreement is subject to regulatory approvals and other customary closing conditions. Once completed, the investment is expected to have a positive impact on both companies' financial performance and market position. REPUBLIC HC's decision to invest in Langu Valley Biotechnology through a capital increase and share expansion method demonstrates its commitment to growth and innovation in the biotechnology sector.